May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Topical CoQ10 Is Neuroprotective in Experimental Glaucoma
Author Affiliations & Notes
  • M. Cordeiro
    UCL Institute of Ophthalmology, London, United Kingdom
    Glaucoma & Retinal Neurodegeneration Research Group,
    Western Eye Hospital, London, United Kingdom
  • L. Guo
    UCL Institute of Ophthalmology, London, United Kingdom
    Glaucoma & Retinal Neurodegeneration Research Group,
  • W. Cheung
    UCL Institute of Ophthalmology, London, United Kingdom
    Glaucoma & Retinal Neurodegeneration Research Group,
  • N. Wood
    UCL Institute of Ophthalmology, London, United Kingdom
    Glaucoma & Retinal Neurodegeneration Research Group,
  • T. E. Salt
    UCL Institute of Ophthalmology, London, United Kingdom
    Visual Sciences,
  • Footnotes
    Commercial Relationships M. Cordeiro, Visufarma, F; L. Guo, None; W. Cheung, None; N. Wood, None; T.E. Salt, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4369. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Cordeiro, L. Guo, W. Cheung, N. Wood, T. E. Salt; Topical CoQ10 Is Neuroprotective in Experimental Glaucoma. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4369.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: CoQ10 is a molecule that has been shown to have neuroprotective activity. It is a free radical scavenger being a cofactor of the electron transport chain where it transfers electrons from complexes I and II to complex III. In this study, we investigate the effects of topical CoQ10 using glaucoma-related in vivo rat models of retinal ganglion cell (RGC) apoptosis.

Methods:: Two different rat models of RGC apoptosis were studied. To investigate dose and administration effects, Dark Agouti (DA) rat eyes injected with intravitreal staurosporine (SSP) were randomly assigned to five different treatment groups (n=18/group; x1 or x2 topical CoQ10 (Visufarma srl, Italy) 0.1%, x1 CoQ10 0.05%, or carrier or saline control) given either 4 hours or 30 minutes before or 1 hour after SSP administration under general anaesthesia. Eyes were imaged in vivo using DARC (detection of apoptosing retinal cells), and results confirmed histologically. The most effective dosing regimens were then assessed and compared to control in a chronic ocular hypertension (OHT) rat model with DARC imaging at 3 weeks after IOP elevation (n=10), and histological analysis thereafter.

Results:: CoQ10 0.1% significantly reduced RGC apoptosis compared to CoQ10 0.05% (p<0.05) and carrier (p<0.05) in the SSP model. No benefit was exhibited by increasing the dose to x2. The most effective timing of the treatment application was at 1 hour after SSP administration. CoQ10 0.1% administered 1 hour after IOP elevation in the experimental glaucoma study was found to significantly inhibit the development of RGC apoptosis in vivo at 3 weeks in the OHT model (p<0.05), with efficacy demonstrated both in vivo and histologically.

Conclusions:: These results show that CoQ10 0.1% has a neuroprotective effect not only on SSP-induced but also OHT-induced RGC apoptosis in vivo. CoQ10 has been safely used in patients with Parkinson’s Disease & ALS as an oral medication. Perhaps the most exciting finding in this study is the demonstration of its efficacy as an eyedrop formulation. We believe CoQ10 represents a promising neuroprotective topical treatment in glaucoma with clinical trials planned shortly.

Keywords: neuroprotection • apoptosis/cell death • ganglion cells 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×